Latest Articles

  • When should we consider SGLT-2 inhibitors in patients with acute decompensated heart failure?
    Cleveland Clinic Journal of Medicine February 2024, 91 (2) 118;

    In the January 2024 issue, the article “When should we consider SGLT-2 inhibitors in patients with acute decompensated heart failure?” by Badwan OZ et al [Cleve Clin J Med 2024; 91(1):47–51. doi:10.3949/ccjm.91a.23034] contained an error in Figure 1.

  • Should I start an SGLT-2 inhibitor in my patient with heart failure and chronic kidney disease?
    Taher Modarressi, MD
    Cleveland Clinic Journal of Medicine February 2024, 91 (2) 82; DOI: https://doi.org/10.3949/ccjm.91c.02001
  • Our Peer-Reviewers for 2023
    Cleveland Clinic Journal of Medicine February 2024, 91 (2) 85;
  • Gastric intestinal metaplasia and gastric cancer prevention: Watchful waiting
    Shrouq Khazaaleh, MD, Mohammad Alomari, MD, Mamoon Ur Rashid, MD, Daniel Castaneda, MD and Fernando J. Castro, MD
    Cleveland Clinic Journal of Medicine January 2024, 91 (1) 33-39; DOI: https://doi.org/10.3949/ccjm.91a.23015

    Malignancy develops in only a small minority of patients with gastric intestinal metaplasia. Recognition of clinical, endoscopic, and histologic features linked with cancer development is critical to identifying patients who require endoscopic surveillance.

  • Nonstatin therapy to reduce low-density lipoprotein cholesterol and improve cardiovascular outcomes
    Abhayjit Singh, MD and Leslie S. Cho, MD
    Cleveland Clinic Journal of Medicine January 2024, 91 (1) 53-63; DOI: https://doi.org/10.3949/ccjm.91a.23058

    Several new nonstatin medications have been approved in recent years, with robust data from clinical trials supporting their use in atherosclerotic disease.

  • Conjunctival petechiae in infective endocarditis
    Akinori Sekizawa, MD, Ayaka Nagano, MD, Kenichi Hashimoto, MD, PhD and Yosuke Ono, MD, PhD
    Cleveland Clinic Journal of Medicine January 2024, 91 (1) 20-21; DOI: https://doi.org/10.3949/ccjm.91a.23041

    A 75-year-old-man presented with a 33-day history of intermittent nocturnal fevers of 39°C (102°F) and truncal rashes. The rashes appeared on the same day as the fever.

  • It’s a new year, looking back and looking forward
    Brian F. Mandell, MD, PhD
    Cleveland Clinic Journal of Medicine January 2024, 91 (1) 15-16; DOI: https://doi.org/10.3949/ccjm.91b.01024

    Reflections on highlights from 2023 and impending changes in 2024, along with some acknowledgments and farewells.

  • Wearable cardiac monitors: Where do we stand?
    Jakub Sroubek, MD, PhD
    Cleveland Clinic Journal of Medicine January 2024, 91 (1) 31-32; DOI: https://doi.org/10.3949/ccjm.91a.23081

    Wearable monitors perform well as screening tools for atrial fibrillation, but questions remain: Can they help with stroke prevention, what is their role in patients with known atrial fibrillation, and how do we streamline interpretation?

  • Late complications after allogeneic hematopoietic cell transplant
    Pelin Batur, MD, FACP, MSCP
    Cleveland Clinic Journal of Medicine January 2024, 91 (1) 19; DOI: https://doi.org/10.3949/ccjm.91c.01001
  • Consumer-grade wearable cardiac monitors: What they do well, and what needs work
    Consumer-grade wearable cardiac monitors: What they do well, and what needs work
    Abdilahi Mohamoud, MBBS, Joseph Jensen, MD and Kevin G. Buda, DO
    Cleveland Clinic Journal of Medicine January 2024, 91 (1) 23-29; DOI: https://doi.org/10.3949/ccjm.91a.23030

    The authors review common consumer-grade wearables, including the accuracy of these monitors compared with medical-grade devices, and present an approach to managing rate or rhythm abnormalities identified on at-home monitoring.

Pages